352 drugs transferred out of Beijing Medical Insurance catalogue

352 drugs were transferred out of the medical insurance catalogue of Beijing; meanwhile, the medical insurance catalogue of Hebei Province was circulated in the industry Within three years, 498 varieties were gradually transferred out of the medical insurance catalogue On December 27, the Beijing Municipal Medical Security Bureau issued the document "notice on adjusting the reimbursement scope of drugs for basic medical insurance, work injury insurance and maternity insurance in this city" This notice shall be implemented as of January 1, 2020 According to the notice, the drugs deleted from the national medical insurance drug catalogue such as rhubarb sodium bicarbonate oral regular release dosage form and the drugs under the state key monitoring scope are deleted from the reimbursement scope of basic medical insurance, work injury insurance and maternity insurance drugs in this city The list of deleted drugs is attached in the annex According to the statistics of cypress blue, there are 281 Western medicines and 71 Chinese patent medicines in total, 352 in total - 352 varieties, which have been transferred out of the Beijing medical insurance catalog Coincidentally, a notice of Hebei Medical Security Bureau and Hebei human resources and social security department on printing and distributing the directory of drugs for basic medical insurance, work injury insurance and maternity insurance (2019 version) has been circulated in the industry According to the notice, Hebei basic medical insurance, work injury insurance and maternity insurance drug catalog (2019 version) (hereinafter referred to as "drug catalog") has been developed in combination with the actual situation of Hebei Province, the Provincial Medical Security Bureau and the Department of human resources and social security, and has been officially implemented since January 1, 2020 The document shall be clear and strictly implement the drug catalog It is not allowed to make the catalog or add drugs in the catalog by changing, limit the trade name of drugs, and adjust the limited payment scope and relevant regulations of drugs Industrial injury insurance is not limited to the scope of payment when it pays for drugs The original supplementary class B drugs in Hebei Province shall be transferred out of the drugs that are included in the key monitoring scope of the state and our province in priority, and a catalogue of supplementary drugs in Hebei Province shall be kept temporarily, which will be gradually digested by the Provincial Medical Security Bureau within three years According to the statistics of cypress blue, there are 498 varieties in the provincial supplement catalogue, including 286 Western medicines and 212 Chinese patent medicines To some extent, if the documents are true, according to relevant regulations, the 498 drugs will be gradually transferred out of the medical insurance catalog of Hebei Province in the next three years Up to now, four provinces (cities) have published the list of medical insurance catalog On December 17, Sichuan Medical Insurance Bureau issued a notice that the national drug catalog will be fully implemented from January 1, 2020, and 275 Western medicines and 71 Chinese patent medicines will be removed from the Sichuan Medical insurance catalog It is clear in the document that if the provincial supplementary catalogue has been included in the national drug catalogue, it shall be implemented in accordance with the national regulations; if it has not been included, it shall be implemented temporarily in accordance with the original regulations and gradually digested within three years; the deleted varieties in the national drug catalogue shall not be implemented On December 13, Hunan Medical Insurance Bureau and the Department of human resources and Social Security jointly issued a notice to digest the supplementary medical insurance drugs of the original province year by year, preferentially remove the first batch of national key monitoring catalog varieties, transfer out the original catalog varieties of the province that have entered the national drug catalog, and then classify them as the "drug parts in the digestion period" These varieties will be digested year by year in accordance with the national regulations, and the medical insurance scope will be cleared up Wai There are 404 varieties involved, of which 212 are western medicine and 192 are Chinese patent medicine There are different names From the deletion of varieties in the national drug catalog of Sichuan Province, to the "digestion period drug part" of Hunan Province, to the "temporarily reserved province supplement catalog" of Hebei Province, when the local government issued relevant policies, it followed the requirements of the "three-year transition period" of the National Bureau, and the overall measures were relatively peaceful According to the past data, taking the 2017 provincial medical insurance catalogue published by each province as an example, Hebei Province has the largest number of added varieties, reaching 635, Jiangxi Province has the largest number of added varieties of Western medicine, with 451; Beijing has the largest number of added varieties of traditional Chinese medicine, with a total of 255 As a major province of medicine, Hebei Province, which added the most varieties in 2017, has started to take action, or will play a leading role in other provinces To this end, a marketing person who has worked in the pharmaceutical industry for many years said to saberland, "the provinces have given pharmaceutical enterprises and medical institutions a three-year buffer period, mainly considering the national policies, after all, it involves complicated interest chain relations; moreover, it is still a loss to consider the stability of enterprises, platforms and agents, patient compliance and other factors, if all are taken into consideration Sex " Jia Xiaoqing, the purchasing manager of the retail department of Jiangsu Pharmaceutical Co., Ltd., also expressed the same view: on the one hand, it is to consider the change of local drug habits; on the other hand, it is to consider the feelings of the industry, so that the industry has the opportunity to transform If we do not set a buffer period, the problem of dealing with the supply of existing medical institutions will be very difficult He explained: the purpose of setting a three-year buffer period is to let those who go out still have a chance to come in As long as they meet the basic drug catalog standards, do a good job in secondary research and development, evidence-based medicine, etc., they can still enter the medical insurance again The goal of national reform is to let the health insurance fund be used on the cutting edge, not to kill some enterprises Previously, the official news clearly proposed the adjustment method of the provincial supplement to the medical insurance drug Catalog: the local supplement was digested and completed within three years according to the principle of 442, respectively according to 40%, 40% and 20% of the provincial supplement quantity, and the auxiliary drugs were monitored and removed from the catalog first Although there are proportions, there are no specific standards and rules The above anonymous person told cypress blue: Although the document did not clearly say, but from the perspective of the national policy trend, it must be a non urgent, unimportant and auxiliary variety with unclear clinical efficacy, which was transferred out of the provincial supplement directory first He further added, but the overall impact is not significant, because the national health insurance catalog already covers the drugs in short supply, urgent need and in short supply, and the provincial supplement varieties will basically have alternative products in the hospital catalog, so there is no need to worry about this problem Basically, if the supplementary varieties fail to enter the national health insurance catalog within three years, there is no other way to think about it According to the aforementioned senior personage, after all, there is a three-year transition period for pharmaceutical enterprises' products, which will not be taken out of the hospital and can be covered, but it is impossible to think about the quantity, because the quantity of the hospital is for the varieties in the medical insurance catalog, the consistency evaluation varieties, and the 4 + 7 varieties, so it is difficult for the self funded drugs to be measured, and pharmaceutical enterprises will not make great efforts to cultivate teams and promote products "In the future, these products can be sold in the hospital as part of the cash flow, but the focus of the enterprise should be adjusted to how to find the future direction, such as the field of new products, how to transform research and development - if the future drugs need to go to self funded drugs, there is no need to spend too much effort and resources." At present, as the largest buyer and payer of medical and health care in China, the State Medical Insurance Bureau will release medical insurance funds to replace birds, opening up space for the adjustment of medical insurance drug structure Before that, the original research drugs and auxiliary drugs with expired patents consumed a lot of medical insurance funds, and the medical insurance bureau made the original research drugs lose super national treatment through 4 + 7 volume procurement; on the other hand, it blocked the way of "saving the country by curve" of some products by focusing on monitoring the rational drug use catalogue and prohibiting local supplement of medical insurance varieties As Dickens said, this is the best era, this is the worst era; for the pharmaceutical industry, this is the worst era and a new beginning, he said The direction of the country has been clear, that is to let enterprises do valuable and innovative products; only when enterprises embrace national policies, do consistency evaluation, do consistency evaluation, do innovation, do innovation, can they win from the competition Because it is difficult to have a large amount of space for drugs, enterprises will no longer invest in resources and human resources, and the pharmaceutical representatives involved will also usher in career changes.